Abbott Laboratories Analyst Ratings
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)
Barclays Keeps Their Buy Rating on Abbott Laboratories (ABT)
Abbott Laboratories Analyst Ratings
RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $125 Price Target
Abbott: Goldman Sachs starts reporting with a buy rating; target share price is $121
Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115
Abbott Laboratories (ABT.US) was first covered by Goldman Sachs and given a buy rating, with a target price of $121.00.
Abbott Laboratories Analyst Ratings
Goldman Sachs Initiates Coverage On Abbott Laboratories With Buy Rating, Announces Price Target of $121
Optimistic Buy Rating for Abbott Laboratories on Diverse Portfolio and Growth Prospects
Critical Insights From Abbott Laboratories Analyst Ratings: What You Need To Know
Abbott Laboratories Analyst Ratings
Citi: Maintains the Abbott Laboratories (ABT.US) rating, adjusted from buy to buy rating, and adjusted the target price from $128.00 to $119.00.
Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)
Analysts Conflicted on These Healthcare Names: Abbott Laboratories (ABT), PolyPid (PYPD) and GoodRx Holdings (GDRX)
Buy Rating Affirmed for Abbott Laboratories Based on Strong EP Business and Strategic Growth Prospects
RBC Capital Keeps Their Buy Rating on Abbott Laboratories (ABT)